A total of 237 studies were screened for eligibility, out of which 4 Phase 3–4 RCTs assessing the strategy of NOAC with either a P2Y12 inhibitor or DAPT vs. VKA (primarily represented by warfarin) with a P2Y12 inhibitor or DAPT in AF patients following PCI were included in the final analysis (Supplementary Figure S1). Here, P2RY12 is linked to atrial fibrillation.